Recordati : Recordati continued to improve its margin in H1
>H1 2018 earnings up 7% - Recordati reported its H1 2018 results on Thursday, 26 July at midday. Revenues totalled € 696.1m, up 6.9% (Q1, +7.2% / Q2, +6.7%). The franchise of "corporate" products (one-third of sales) benefited from a favourable comparative base with the acquisition of Seloken which is consolidated since 1 July 2017. Growth reached 33% in H1 (+4% excl. Seloken). Note that sales of Seloken (hypertension and cardiac failure) halted their decline and coul...Recordati-Industria Chimica e Farmaceutica is a pharmaceutical group based in Italy. Co.'s operations are divided into two operating segments: pharmaceuticals (and pharmaceutical chemicals) and orphan drugs. Co.'s products include ZANIPRESS®/ZANEXTRA®/LERCAPREL®/LERCARIL®, an antihypertensive drug; ZANIDIP®/CORIFEO®/LERCADIP® (lercanidipine), an antihypertensive drug discovered and developed in Co.'s research laboratories; UROREC® (silodosin), a new drug indicated for the treatment of benign prostatic hyperplasia; and LIVAZO®/ALIPZA® (pitavastatin), a statin for the treatment of dyslipidemia, among others.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.